Characteristics and outcome of patients with IFI
| Characteristics of patients . | Number of patients (n = 33) . |
|---|---|
| Gender | |
| Male | 22 |
| Female | 11 |
| Age, years | |
| Median [range] | 70 [31-82] |
| Number of previous lines of treatment | |
| Median [range] | 2 [0-4] |
| 17p deletions | 15/30 CLL |
| Interval between last line and ibrutinib (months) | |
| Median [range] | 10.5 [1-96] |
| Hypogammaglobulinemia | |
| Yes [intravenous immunoglobulins substitution] | 31 [8] |
| No | 2 |
| Additional predisposing factors for IFI | |
| Neutropenia [grade 4] | 5 [2] |
| Corticosteroids | 4 |
| Rituximab + corticosteroids | 3 |
| Rituximab | 2 |
| Concomitant immunochemotherapy | 3 |
| Chemotherapy ≤6 mo | 10 |
| Diabetes mellitus | 2 |
| Cirrhosis | 1 |
| Azathioprine | 1 |
| HIV | 1 |
| Characteristics of patients . | Number of patients (n = 33) . |
|---|---|
| Gender | |
| Male | 22 |
| Female | 11 |
| Age, years | |
| Median [range] | 70 [31-82] |
| Number of previous lines of treatment | |
| Median [range] | 2 [0-4] |
| 17p deletions | 15/30 CLL |
| Interval between last line and ibrutinib (months) | |
| Median [range] | 10.5 [1-96] |
| Hypogammaglobulinemia | |
| Yes [intravenous immunoglobulins substitution] | 31 [8] |
| No | 2 |
| Additional predisposing factors for IFI | |
| Neutropenia [grade 4] | 5 [2] |
| Corticosteroids | 4 |
| Rituximab + corticosteroids | 3 |
| Rituximab | 2 |
| Concomitant immunochemotherapy | 3 |
| Chemotherapy ≤6 mo | 10 |
| Diabetes mellitus | 2 |
| Cirrhosis | 1 |
| Azathioprine | 1 |
| HIV | 1 |
| Characteristics of invasive fungal infection . | |
|---|---|
| Interval between start of ibrutinib and diagnosis of IFI (months) | |
| Median [range] | 3 [1-30] |
| Ibrutinib dose at diagnosis of IFI (mg/d) | |
| 280 | 3 |
| 420 | 29 |
| 560 | 1 |
| Type of infection | |
| IA | 27 |
| Category | |
| Proven | 17 |
| Probable | 9 |
| Possible | 1 |
| Localization | |
| Pulmonary | 15 |
| Pulmonary + CNS | 10 |
| CNS + muscle abscess | 1 |
| Sinus | 1 |
| Cryptococcosis | 4 |
| Pneumocystis pneumonia | 1 |
| Mucormycosis | 1 |
| Isolated microorganism | |
| Aspergillus fumigatus | 16 |
| Aspergillus nidulans | 1 |
| Zygomycetes (Lichtheimia corymbifera) | 1 |
| Cryptococcus neoformans | 3 |
| Pneumocystis jirovecii | 1 |
| Outcome | |
| Alive at last follow-up | 16 |
| Death | 17 |
| Because of IFI | 9 |
| Because of CLL | 5 |
| Other causes | 3 |
| Characteristics of invasive fungal infection . | |
|---|---|
| Interval between start of ibrutinib and diagnosis of IFI (months) | |
| Median [range] | 3 [1-30] |
| Ibrutinib dose at diagnosis of IFI (mg/d) | |
| 280 | 3 |
| 420 | 29 |
| 560 | 1 |
| Type of infection | |
| IA | 27 |
| Category | |
| Proven | 17 |
| Probable | 9 |
| Possible | 1 |
| Localization | |
| Pulmonary | 15 |
| Pulmonary + CNS | 10 |
| CNS + muscle abscess | 1 |
| Sinus | 1 |
| Cryptococcosis | 4 |
| Pneumocystis pneumonia | 1 |
| Mucormycosis | 1 |
| Isolated microorganism | |
| Aspergillus fumigatus | 16 |
| Aspergillus nidulans | 1 |
| Zygomycetes (Lichtheimia corymbifera) | 1 |
| Cryptococcus neoformans | 3 |
| Pneumocystis jirovecii | 1 |
| Outcome | |
| Alive at last follow-up | 16 |
| Death | 17 |
| Because of IFI | 9 |
| Because of CLL | 5 |
| Other causes | 3 |